- Drugs
- Monday, 27 Apr 2020
Alligator Bioscience Presents Promising Interim Phase I Data for its Bispecific Drug Candidate ATOR-1015 at AACR
Alligator Bioscience, announces that the company today presents the status of the ongoing Phase I clinical trial with the bispecific drug candidate ATOR-1015 developed as tumor-directed therapy for metastatic cancer. The presentation will take place at the AACR (American Association for Cancer Research) Annual Meeting, which this year is being held digital for the first time.
This far, doses of 400 mg (about 6 mg/kg) have been evaluated in the ongoing study and the current dosing is 600 mg (about 10 mg/kg). 18 patients with varying cancer forms (colon cancer, eye melanoma, pancreatic cancer, ovarian cancer, gallbladder cancer, gastric cancer and skin cancer) have been treated and evaluated in terms of safety. ATOR-1015 has so far been well tolerated.
"We are very proud and happy that our study has been selected for presentation. The promising results so far demonstrate that ATOR-1015 can be administered safely. ATOR-1015 has the potential to be at least as effective as today's available treatment for these patients, but with significantly fewer side effects," said Per Norlén, CEO of Alligator Bioscience.
The adverse events in the study were generally mild and transient, all of grade 1 or 2 (on a scale of 1-5). The most common adverse events were infusion-related reactions (five patients). No serious immune-related or dose-limiting adverse events have been reported.
The presentation with the title "A first-in-human phase 1 study in patients with advanced and/or refractory solid malignancies to evaluate the safety of ATOR-1015, a CTLA-4 x OX40 bispecific antibody" will be held by Charlotte Russell, Chief Medical Officer at Alligator Bioscience. The presentation is available through the link below between 9:00 a.m. - 6:00 p.m. EDT (3 p.m.-12 a.m. CEST) today and will also be available on the company website www.alligatorbioscience.com. https://www.abstractsonline.com/pp8/#!/9045/presentation/10644
Related Industry Updates
The ITC Complaint Against Estar Medical in the U.S. Is Withdrawn by Regenlab
Mar 05, 2020
Sanofi says COVID-19 vaccine will be available globally at the same time
May 15, 2020
Moderna picks drugmaker Catalent to manufacture potential COVID-19 vaccine
Jun 25, 2020
Global Generic Oncology Drugs Market | Competitive Dynamics & Outlook 2027 - Key Players: Aurobindo Pharma , Intas Pharmaceuticals , Zydus Cadila , Mylan N.V. , Cipla Inc. , Fresenius Kabi AG , Dr. Reddy’s Laboratories Ltd, etc
May 03, 2021
Sialorrhea Treatment Market is expected to reach US$ 1,042.37 million by 2030
Dec 12, 2023
Small Cell Lung Cancer (SCLC) Treatment Market is expected to reach US$ 9,173.60 million by 2030
Dec 21, 2023
Asia Pacific Transdermal Drug Delivery System Market Prospects & Upcoming Trends and Opportunities Upto 2027
Sep 05, 2020
Follow us on
